Skip to content
10-K

Annual Report

SYROS PHARMACEUTICALS, INC.

0000950170-24-036808

← back to feed
Filed
Mar 27, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 6, 2024 26.45M sh
Shares Diluted FY 2023 · Dec 31, 2023 28.33M sh
Shares Diluted FY 2023 · Dec 31, 2022 12.63M sh
Capex FY 2023 · Dec 31, 2023 $272K
Capex FY 2023 · Dec 31, 2022 $1.24M
Operating Cash Flow FY 2023 · Dec 31, 2023 −$109.71M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$123.07M
Long Term Debt FY 2023 · Dec 31, 2023 $34.56M
Long Term Debt FY 2023 · Dec 31, 2022 $40.65M
Short Term Debt FY 2023 · Dec 31, 2023 $6.67M
Cash And Equivalents FY 2023 · Dec 31, 2023 $139.53M
Cash And Equivalents FY 2023 · Dec 31, 2022 $167.47M
Stockholders Equity FY 2023 · Dec 31, 2023 $16.66M
Stockholders Equity FY 2023 · Dec 31, 2022 $127.74M
Stockholders Equity FY 2023 · Dec 31, 2021 $85.22M
Current Liabilities FY 2023 · Dec 31, 2023 $36.68M
Current Liabilities FY 2023 · Dec 31, 2022 $30.78M
Current Assets FY 2023 · Dec 31, 2023 $144.98M
Current Assets FY 2023 · Dec 31, 2022 $211.39M
Total Assets FY 2023 · Dec 31, 2023 $168.17M
Total Assets FY 2023 · Dec 31, 2022 $244.49M
Eps Diluted FY 2023 · Dec 31, 2023 −$5.81
Eps Diluted FY 2023 · Dec 31, 2022 −$7.49
Eps Basic FY 2023 · Dec 31, 2023 −$5.81
Eps Basic FY 2023 · Dec 31, 2022 −$7.49
Sga Expense FY 2023 · Dec 31, 2023 $28.28M
Sga Expense FY 2023 · Dec 31, 2022 $29.3M
Rd Expense FY 2023 · Dec 31, 2023 $108.15M
Rd Expense FY 2023 · Dec 31, 2022 $111.94M
Net Income FY 2023 · Dec 31, 2023 −$164.57M
Net Income FY 2023 · Dec 31, 2022 −$94.65M
Operating Income FY 2023 · Dec 31, 2023 −$128.99M
Operating Income FY 2023 · Dec 31, 2022 −$135.87M
Revenue FY 2023 · Dec 31, 2023 $9.94M
Revenue FY 2023 · Dec 31, 2022 $14.88M